The University of Chicago Header Logo

Connection

Stuart Sprague to Middle Aged

Back to Details
This is a "connection" page, showing publications Stuart Sprague has written about Middle Aged.
Stuart Sprague
Connection Strength
0.882
Middle Aged
  1. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
    View in: PubMed
    Score: 0.058
  2. Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study. Kidney360. 2024 05 01; 5(5):732-742.
    View in: PubMed
    Score: 0.053
  3. Secondary Hyperparathyroidism in a Patient with CKD. Clin J Am Soc Nephrol. 2020 07 01; 15(7):1041-1043.
    View in: PubMed
    Score: 0.041
  4. Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease. Am J Nephrol. 2019; 49(2):114-124.
    View in: PubMed
    Score: 0.037
  5. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 10; 22(4):480-491.
    View in: PubMed
    Score: 0.035
  6. Factors associated with health-related quality of life, hip function, and health utility after operative management of femoral neck fractures. Bone Joint J. 2018 03 01; 100-B(3):361-369.
    View in: PubMed
    Score: 0.035
  7. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data?. Clin Nephrol. 2017 Aug; 88(8):59-67.
    View in: PubMed
    Score: 0.034
  8. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325.
    View in: PubMed
    Score: 0.032
  9. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12.
    View in: PubMed
    Score: 0.031
  10. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016 Apr; 67(4):559-66.
    View in: PubMed
    Score: 0.029
  11. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30.
    View in: PubMed
    Score: 0.029
  12. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014; 40(6):535-45.
    View in: PubMed
    Score: 0.028
  13. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 05; 9(9):1620-6.
    View in: PubMed
    Score: 0.027
  14. Painful skin ulcers in a hemodialysis patient. Clin J Am Soc Nephrol. 2014 Jan; 9(1):166-73.
    View in: PubMed
    Score: 0.026
  15. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8.
    View in: PubMed
    Score: 0.019
  16. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76.
    View in: PubMed
    Score: 0.019
  17. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85.
    View in: PubMed
    Score: 0.018
  18. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106.
    View in: PubMed
    Score: 0.017
  19. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43.
    View in: PubMed
    Score: 0.016
  20. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006 Feb; 47(2):263-76.
    View in: PubMed
    Score: 0.015
  21. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005 Nov-Dec; 25(6):591-5.
    View in: PubMed
    Score: 0.015
  22. Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
    View in: PubMed
    Score: 0.014
  23. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024 Jun; 41(6):2500-2518.
    View in: PubMed
    Score: 0.013
  24. Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with CKD. Kidney360. 2024 05 01; 5(5):681-689.
    View in: PubMed
    Score: 0.013
  25. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr; 63(4):1483-90.
    View in: PubMed
    Score: 0.012
  26. Medullary Blood Oxygen Level-Dependent MRI Index (R2*) is Associated with Annual Loss of Kidney Function in Moderate CKD. Am J Nephrol. 2020; 51(12):966-974.
    View in: PubMed
    Score: 0.011
  27. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
    View in: PubMed
    Score: 0.010
  28. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clin J Am Soc Nephrol. 2020 06 08; 15(6):776-783.
    View in: PubMed
    Score: 0.010
  29. A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. J Am Soc Nephrol. 2020 01; 31(1):161-174.
    View in: PubMed
    Score: 0.010
  30. Renal BOLD MRI in patients with chronic kidney disease: comparison of the semi-automated twelve layer concentric objects (TLCO) and manual ROI methods. MAGMA. 2020 Feb; 33(1):113-120.
    View in: PubMed
    Score: 0.010
  31. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170.
    View in: PubMed
    Score: 0.010
  32. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019 10; 96(4):1030-1036.
    View in: PubMed
    Score: 0.009
  33. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol. 2019 06; 30(6):1096-1108.
    View in: PubMed
    Score: 0.009
  34. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293.
    View in: PubMed
    Score: 0.009
  35. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999 Mar; 14(3):456-63.
    View in: PubMed
    Score: 0.009
  36. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. J Diabetes Complications. 2018 Dec; 32(12):1113-1117.
    View in: PubMed
    Score: 0.009
  37. Consistency of Multiple Renal Functional MRI Measurements Over 18 Months. J Magn Reson Imaging. 2018 08; 48(2):514-521.
    View in: PubMed
    Score: 0.009
  38. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1918-1926.
    View in: PubMed
    Score: 0.009
  39. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017 Aug 01; 32(8):1330-1338.
    View in: PubMed
    Score: 0.008
  40. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016 Feb; 29(1):63-70.
    View in: PubMed
    Score: 0.007
  41. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Jun; 30(6):1037-46.
    View in: PubMed
    Score: 0.007
  42. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014 Sep; 86(3):638-47.
    View in: PubMed
    Score: 0.007
  43. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis. 1993 Aug; 22(2):300-7.
    View in: PubMed
    Score: 0.006
  44. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992 Jun; 19(6):532-9.
    View in: PubMed
    Score: 0.006
  45. Serum amyloid P component: a predictor of clinical beta 2-microglobulin amyloidosis. Am J Kidney Dis. 1992 May; 19(5):427-32.
    View in: PubMed
    Score: 0.006
  46. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010 Apr; 14(2):182-92.
    View in: PubMed
    Score: 0.005
  47. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010 Jul; 20(4):243-54.
    View in: PubMed
    Score: 0.005
  48. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct; 148(10):2169-72.
    View in: PubMed
    Score: 0.005
  49. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1437-45.
    View in: PubMed
    Score: 0.004
  50. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med. 1986 Oct; 146(10):2063-4.
    View in: PubMed
    Score: 0.004
  51. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93.
    View in: PubMed
    Score: 0.004
  52. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May; 43(5):877-90.
    View in: PubMed
    Score: 0.003
  53. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54.
    View in: PubMed
    Score: 0.003
  54. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl. 2002 Oct; (81):S23-33.
    View in: PubMed
    Score: 0.003
  55. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000 May; 15(5):927-35.
    View in: PubMed
    Score: 0.003
  56. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol. 1998 Apr; 9(4):677-83.
    View in: PubMed
    Score: 0.002
  57. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg. 1989 Dec; 98(6):1107-12.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.